Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blinded, Randomized, Placebo Controlled Study of NVX-108 With Radiation & Temozolomide and During Maintenance Phase With Temozolomide in Newly-diagnosed Glioblastoma Multiforme

Trial Profile

Double-blinded, Randomized, Placebo Controlled Study of NVX-108 With Radiation & Temozolomide and During Maintenance Phase With Temozolomide in Newly-diagnosed Glioblastoma Multiforme

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perflenapent (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors NuvOx Pharma
  • Most Recent Events

    • 29 Sep 2017 According to National Cancer Institute media release, National Cancer Institute (NCI) has awarded a grant for up to $3 million to NuvOx Pharma to initiate this trial.
    • 28 Aug 2017 According to a NuvOx Pharma media release, this trial will be led by Dr. Baldassarre Stea from the University of Arizona. The trial will be conducted at Banner MD Anderson, Banner-University Medical Center Tucson, Barrow Neurological Institute and Miami Cancer Institute.
    • 18 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top